Project Grant R01DA062380
Award Date
9/30/24
Completion Date
7/31/29
Dollars Obligated
$1.5M
Federal Agency
National Institute on Drug Abuse
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award in the amount of $983,672.00 was issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award will fund research to characterize the in-situ spatial interactions between HIV-infected cells and immune cells in the central nervous system (CNS) of people living with HIV, with a focus on understanding the impact of methamphetamine use on neuroinflammation. The research will leverage a unique cohort of brain...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of methamphetamine and the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis in promoting HIV persistence and brain injury in the presence of antiretroviral therapy (ART). The $804,728 award to the Regents of the University of California at Riverside will support in vitro and in vivo...
This $2,223,769 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under CFDA 93.279 - Drug Use and Addiction Research Programs aims to uncover the intersection between HIV infection and opioid use in driving neuroinflammation and neurotoxicity. The University of California, San Diego (UCSD) will lead a comprehensive research effort using archived and fresh human brain tissue specimens to: Determine the relationship between HIV activity, opioid exposure, and inflammasome...
This $1,372,480 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to elucidate the molecular mechanisms by which HIV Tat protein, cocaine, and combination antiretroviral therapy (cART) contribute to microglial pyroptosis and neuroinflammation in the context of HIV-associated neurocognitive disorders (HAND). The key objectives are to 1) determine the molecular mechanisms underlying...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $2,312,085 to Boston University Medical Campus to investigate the molecular mechanisms linking HIV infection and opioid use disorder that drive neuroinflammation and HIV-associated neurocognitive disorders (HAND). The project will utilize primary human iPSC-derived microglia cultures to study how HIV infection and opioid exposure activate the NLRP1...
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,738,976 to Wake Forest University Health Sciences to investigate the neuroimmune pathways linking chronic psychosocial stress to co-occurring stimulant use and depression in people living with HIV (PWH). The study aims to: 1) Investigate the causal link between an evidence-based positive affect intervention (ARTEMIS) and neural functioning in...
This Project Grant award of $234,000.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to understand the impact of opioids on HIV transcription and latency. The research will utilize a novel dual fluorescent and bioluminescent HIV virus to visualize and measure the effects of opioids like fentanyl, morphine, and methadone on HIV proviral transcription in microglia and astrocytes. The goal is to identify key...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $687,416 to the J. David Gladstone Institutes in San Francisco, California. The funding supports research aimed at developing therapeutic interventions to suppress the HIV reservoir in people living with both HIV and substance use disorder (SUD). Specifically, the research objectives are to: 1) Determine how inhibiting the host protein CDK9...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,812,966 to The Medical University of South Carolina (MUSC) and The Trustees of Columbia University in the City of New York to conduct research on the impacts of drug abuse on the development of anti-CD4 autoantibodies and immune reconstitution in HIV patients. The key objectives are to: 1) Determine the mechanisms of affinity maturation and...